9:00 AM - 9:15 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
IBI is a recent spin out from Interface Biologics, Inc. following the sale of its Surface Modification business. IBI is focused on a novel, non-polymeric, small molecule prodrug platform which provides sustained zero-order release kinetics across a broad range of drug classes and form factors. Our initial product focus is an intravitreal dexamethasone prodrug implant targeting diabetic macular edema, retinal vein occlusion and non-infectious uveitis - collectively a $1B+ market opportunity. The target product profile is to have zero-order drug release for 9-12 months with 1/10th the drug loading of the market leading commercial product with a 30g needle. With strong pre-clinical data and a 505(b)(2) pathway confirmed with the FDA, we are targeting a Phase II clinical trial in mid 2020. Our pipeline product focus areas include other ophthalmic prodrug applications as well as pain management therapies using our steroidal prodrug platform.
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
IBE-814 dexamethasone prodrug intravitreal injection
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided